About Adicet Bio, Inc.
https://www.adicetbio.comAdicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
CEO
Chen Schor BA, CPA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-30 | Reverse | 1:16 |
| 2020-09-16 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Citizens Capital Markets
Market Perform
JMP Securities
Market Perform
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:11.45M
Value:$94.9M
TANG CAPITAL MANAGEMENT LLC
Shares:8.22M
Value:$68.17M
RA CAPITAL MANAGEMENT, L.P.
Shares:7.54M
Value:$62.51M
Summary
Showing Top 3 of 67
About Adicet Bio, Inc.
https://www.adicetbio.comAdicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $27.95M ▼ | $-26.86M ▲ | 0% | $-4.64 ▲ | $-25.27M ▲ |
| Q2-2025 | $0 | $32.39M ▲ | $-31.22M ▼ | 0% | $-5.44 ▼ | $-29.56M ▼ |
| Q1-2025 | $0 | $29.89M ▼ | $-28.21M ▲ | 0% | $-4.96 ▲ | $-26.53M ▲ |
| Q4-2024 | $0 | $30.74M ▼ | $-28.73M ▲ | 0% | $-5.12 ▲ | $-27.1M ▲ |
| Q3-2024 | $0 | $33.15M | $-30.48M | 0% | $-5.44 | $-28.89M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $103.1M ▼ | $140.48M ▼ | $31.34M ▲ | $109.14M ▼ |
| Q2-2025 | $124.96M ▼ | $162.97M ▼ | $29.6M ▼ | $133.37M ▼ |
| Q1-2025 | $150.44M ▼ | $191.27M ▼ | $29.82M ▼ | $161.45M ▼ |
| Q4-2024 | $176.3M ▼ | $220.22M ▼ | $33.61M ▼ | $186.61M ▼ |
| Q3-2024 | $202.06M | $245.96M | $34.43M | $211.53M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-26.86M ▲ | $-22.31M ▲ | $16.84M ▼ | $-150K ▼ | $-5.62M ▼ | $-22.52M ▲ |
| Q2-2025 | $-31.22M ▼ | $-26.63M ▼ | $32.95M ▲ | $267K ▲ | $6.59M ▲ | $-26.68M ▲ |
| Q1-2025 | $-28.21M ▲ | $-25.4M ▼ | $-2.86M ▲ | $-104K ▼ | $-28.36M ▲ | $-26.89M ▼ |
| Q4-2024 | $-28.73M ▲ | $-24.1M ▼ | $-22.12M ▲ | $137K ▲ | $-46.08M ▲ | $-24.28M ▼ |
| Q3-2024 | $-30.48M | $-22.01M | $-96.58M | $-96.18K | $-118.59M | $-22.41M |
Revenue by Products
| Product | Q1-2018 | Q2-2018 | Q3-2018 | Q4-2018 |
|---|---|---|---|---|
 Human Health | $90.00M ▲ | $370.00M ▲ | $80.00M ▼ | $80.00M ▲ |
 Performance Chemicals | $50.00M ▲ | $180.00M ▲ | $40.00M ▼ | $40.00M ▲ |
 Pharmaceutical Ingredients | $40.00M ▲ | $160.00M ▲ | $40.00M ▼ | $40.00M ▲ |
Revenue by Geography
| Region | Q2-2018 |
|---|---|
 Asia Pacific | $30.00M ▲ |
 FRANCE | $40.00M ▲ |
 GERMANY | $100.00M ▲ |
 NETHERLANDS | $10.00M ▲ |
 UNITED STATES | $540.00M ▲ |
CEO
Chen Schor BA, CPA,
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-30 | Reverse | 1:16 |
| 2020-09-16 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Guggenheim
Buy
Citizens Capital Markets
Market Perform
JMP Securities
Market Perform
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:11.45M
Value:$94.9M
TANG CAPITAL MANAGEMENT LLC
Shares:8.22M
Value:$68.17M
RA CAPITAL MANAGEMENT, L.P.
Shares:7.54M
Value:$62.51M
Summary
Showing Top 3 of 67